International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 842 - 842
Published: Jan. 20, 2025
Hemoglobin-based oxygen carriers have been developed to compensate the needs of blood for transfusions. Most them were based on intracellular hemoglobin extracted from bovine or human blood, but unfortunately, this type did not pass through last steps clinical trials. In context, HEMARINA discovered a natural extracellular hemoglobin, possessing several advantages avoiding hemoglobin-related side effects. Many preclinical studies assessed safety M101 used in intravenous (IV) injection rodents. To explore IV injections large mammals, six dogs received each single liquid according dose escalation with 48 h follow-up. Then, two monkeys multiple same every hour seven hours. This study showed that and cause histological lesions, nor they induce immunological reactions. makes best candidate date use emergency situations requiring and, diseases, causing hypoxia problems.
Language: Английский